Dykes J R
Postgrad Med J. 1973 May;49(571):314-7. doi: 10.1136/pgmj.49.571.314.
Glucose tolerance and insulin secretion have been measured in six overweight non-diabetic subjects on first presentation and after 5 weeks of fenfluramine treatment without dietary restriction. There was a significant improvement in glucose tolerance and a marginally significant decrease in insulin secretion. In another six overweight non-diabetic subjects, insulin secretion and glucose tolerance were measured on first presentation, after 10 weeks of low-calorie diet, and then after a further 10 weeks of the same low-calorie diet with the addition of fenfluramine. Diet alone did not produce any significant effect on glucose tolerance, but did bring about a significant decrease in insulin secretion. The addition of fenfluramine to the dietary therapy was associated with a marginally significant improvement in the glucose tolerance and a highly significant decrease in insulin secretion. This further decrease in insulin secretion was significantly greater than the decrease produced by diet alone in these six subjects.
对6名超重的非糖尿病受试者在首次就诊时以及接受芬氟拉明治疗5周且未限制饮食后,测量了葡萄糖耐量和胰岛素分泌情况。葡萄糖耐量有显著改善,胰岛素分泌有轻微显著下降。在另外6名超重的非糖尿病受试者中,在首次就诊时、低热量饮食10周后以及再进行10周相同低热量饮食并添加芬氟拉明后,测量了胰岛素分泌和葡萄糖耐量。仅饮食对葡萄糖耐量没有产生任何显著影响,但确实使胰岛素分泌显著下降。在饮食治疗中添加芬氟拉明与葡萄糖耐量有轻微显著改善以及胰岛素分泌显著大幅下降有关。在这6名受试者中,胰岛素分泌的进一步下降显著大于仅饮食所导致的下降。